UG1DA015831
Cooperative Agreement
Overview
Grant Description
THE NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
Awardee
Funding Goals
TO SUPPORT BASIC AND CLINICAL NEUROSCIENCE, BIOMEDICAL, BEHAVIORAL AND SOCIAL SCIENCE, EPIDEMIOLOGIC, HEALTH SERVICES AND HEALTH DISPARITY RESEARCH. TO DEVELOP NEW KNOWLEDGE AND APPROACHES RELATED TO THE PREVENTION, DIAGNOSIS, TREATMENT, ETIOLOGY, AND CONSEQUENCES OF DRUG ABUSE AND ADDICTION, INCLUDING HIV/AIDS. TO SUPPORT RESEARCH TRAINING AND RESEARCH SCIENTIST DEVELOPMENT. TO SUPPORT DISSEMINATION OF RESEARCH FINDINGS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) LEGISLATION IS INTENDED TO EXPAND AND IMPROVE THE SBIR PROGRAMS TO EMPHASIZE AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF TECHNOLOGY DEVELOPED THROUGH FEDERAL SBIR RESEARCH AND DEVELOPMENT, INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN THE SBIR PROGRAM. THE LEGISLATION INTENDS THAT THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
New Haven,
Connecticut
065191361
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 05/31/20 to 02/29/32 and the total obligations have increased 13091% from $858,381 to $113,230,266.
Yale Univ was awarded
Standard versus High Dose ED-Initiated Buprenorphine Induction
Cooperative Agreement UG1DA015831
worth $113,230,266
from National Institute on Drug Abuse in September 2002 with work to be completed primarily in New Haven Connecticut United States.
The grant
has a duration of 29 years 5 months and
was awarded through assistance program 93.279 Drug Abuse and Addiction Research Programs.
The Cooperative Agreement was awarded through grant opportunity Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).
Status
(Ongoing)
Last Modified 9/5/25
Period of Performance
9/30/02
Start Date
2/29/32
End Date
Funding Split
$113.2M
Federal Obligation
$0.0
Non-Federal Obligation
$113.2M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for UG1DA015831
Transaction History
Modifications to UG1DA015831
Additional Detail
Award ID FAIN
UG1DA015831
SAI Number
UG1DA015831-1912459395
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75N600 NIH National Insitute on Drug Abuse
Funding Office
75N600 NIH National Insitute on Drug Abuse
Awardee UEI
FL6GV84CKN57
Awardee CAGE
4B992
Performance District
CT-03
Senators
Richard Blumenthal
Christopher Murphy
Christopher Murphy
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute on Drug Abuse, National Institutes of Health, Health and Human Services (075-0893) | Health research and training | Grants, subsidies, and contributions (41.0) | $76,204,264 | 96% |
| Transfers from the Patient-Centered Outcome Research Trust Fund, Departmental Management, Health and Human Services (075-0145) | Health research and training | Grants, subsidies, and contributions (41.0) | $2,612,370 | 3% |
Modified: 9/5/25